[{"id":"f211649c-22e9-4730-af7a-e9c8ed08f4b3","acronym":"REBELLE","url":"https://clinicaltrials.gov/study/NCT07099443","created_at":"2025-08-02T14:01:04.437Z","updated_at":"2025-08-02T14:01:04.437Z","phase":"","brief_title":"Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL","source_id_and_acronym":"NCT07099443 - REBELLE","lead_sponsor":"Nantes University Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/15/2025","primary_completion_date":" 09/15/2025","study_txt":" Completion: 09/15/2039","study_completion_date":" 09/15/2039","last_update_posted":"2025-08-01"},{"id":"b9dc9326-f8bf-456a-84d5-8c844765d88e","acronym":"M23-647","url":"https://clinicaltrials.gov/study/NCT05753501","created_at":"2023-03-03T15:01:38.988Z","updated_at":"2025-02-25T14:41:53.479Z","phase":"Phase 1","brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies","source_id_and_acronym":"NCT05753501 - M23-647","lead_sponsor":"AbbVie","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" ALK positive","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABBV-101"],"overall_status":"Recruiting","enrollment":" Enrollment 244","initiation":"Initiation: 06/09/2023","start_date":" 06/09/2023","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-14"},{"id":"255cb565-f80f-4c68-9621-5cff2388d8ef","acronym":"NX-5948-301","url":"https://clinicaltrials.gov/study/NCT05131022","created_at":"2022-07-08T17:55:02.950Z","updated_at":"2024-07-02T16:34:59.140Z","phase":"Phase 1","brief_title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","source_id_and_acronym":"NCT05131022 - NX-5948-301","lead_sponsor":"Nurix Therapeutics, Inc.","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bexobrutideg (NX-5948)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 04/13/2022","start_date":" 04/13/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-04"},{"id":"c0336778-22a8-4c11-818f-1fc3b1122699","acronym":"NX-2127-001","url":"https://clinicaltrials.gov/study/NCT04830137","created_at":"2021-04-02T11:53:54.216Z","updated_at":"2024-07-02T16:35:30.165Z","phase":"Phase 1","brief_title":"A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies","source_id_and_acronym":"NCT04830137 - NX-2127-001","lead_sponsor":"Nurix Therapeutics, Inc.","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • BTK C481","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BTK C481"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zelebrudomide (NX-2127)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 05/05/2021","start_date":" 05/05/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-07"}]